new york  reuters    democratic u s  senator claire mccaskill on thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block u s  patent and trademark office review of a patent   drugmaker allergan plc made a deal to transfer some of its patents to a native american tribe two weeks ago in order to shield them from review   mccaskill s response follows a bipartisan u s  house of representatives committee decision to investigate the deal earlier this week and previous calls by democratic senators for a probe   any thinking person would look at what this company did and say   that should be illegal   well  i agree   mccaskill said in a statement   congress never imagined tribes would allow themselves to be used by pharmaceutical companies to avoid challenges to patents  and this bill will shut the practice down before others follow suit   allergan was not immediately available for comment  allergan said last month that it was transferring patents on its blockbuster dry eye medication restasis to new york s saint regis mohawk tribe  which agreed to exclusively license them back to the company in exchange for ongoing payments  the tribe issued a statement expressing outrage at mccaskill s move and accused the senator of engaging in double standards  it said the proposed legislation  specifically targets indian tribes  yet exempts state universities and other sovereign governments engaged in the very same ipr  inter partes review  process   allergan has argued that the legal maneuver is aimed at removing administrative patent challenges through inter partes review by the u s  patent trial and appeal board  and not challenges in federal court  the drugmaker said it believes that the patents should not be subject to the ipr process   which allergan has called flawed and broken   because of the tribe s sovereign immunity  the company still faces a challenge to the patents in federal court  